New Guidelines Give Women More Control Over Cervical Cancer Screening
The American Cancer Society has updated its cervical cancer screening guidelines to endorse the use of self-swab kits to detect human papillomavirus (HPV), which is the leading cause of cervical cancer. This change aims to reduce barriers to cervical cancer screening, particularly among women who may be hesitant or unable to get tested due to concerns about pelvic exams or lack of information.
According to the updated guidelines, women at average risk of cervical cancer can now test for HPV using self-swab kits at home, as long as the results are reliable. This shift from traditional in-clinic testing allows individuals to collect their own specimens and send them to a lab for analysis, reducing wait times and increasing convenience.
The new guidelines also acknowledge that 94% of women prefer home-collection screening methods over traditional clinician-collection tests, citing reliability as a key factor in their preference. The at-home test device approved by the FDA, called the Teal Wand, has been shown to be just as accurate as in-office tests in detecting HPV.
Experts say that these changes can help improve compliance with cervical cancer screening, reducing the risk of developing and dying from the disease. According to the American Cancer Society, cervical cancer incidence and deaths have halved since the 1970s due to improved screening, but rates have plateaued for most groups over the past decade.
The guidelines recommend that individuals at average risk stop being screened after having negative primary HPV tests or negative co-testing using HPV tests and cytology testing (Pap tests) at age 60 and 65. Those who cannot access these tests can opt for three consecutive negative cytology tests, with the last test performed at age 65.
While cervical cancer is often treatable when detected early, barriers to screening remain a significant issue, particularly among women from historically underserved communities. By providing more accessible and convenient testing options, the American Cancer Society hopes to bridge this gap and help reduce the burden of cervical cancer in the US.
The American Cancer Society has updated its cervical cancer screening guidelines to endorse the use of self-swab kits to detect human papillomavirus (HPV), which is the leading cause of cervical cancer. This change aims to reduce barriers to cervical cancer screening, particularly among women who may be hesitant or unable to get tested due to concerns about pelvic exams or lack of information.
According to the updated guidelines, women at average risk of cervical cancer can now test for HPV using self-swab kits at home, as long as the results are reliable. This shift from traditional in-clinic testing allows individuals to collect their own specimens and send them to a lab for analysis, reducing wait times and increasing convenience.
The new guidelines also acknowledge that 94% of women prefer home-collection screening methods over traditional clinician-collection tests, citing reliability as a key factor in their preference. The at-home test device approved by the FDA, called the Teal Wand, has been shown to be just as accurate as in-office tests in detecting HPV.
Experts say that these changes can help improve compliance with cervical cancer screening, reducing the risk of developing and dying from the disease. According to the American Cancer Society, cervical cancer incidence and deaths have halved since the 1970s due to improved screening, but rates have plateaued for most groups over the past decade.
The guidelines recommend that individuals at average risk stop being screened after having negative primary HPV tests or negative co-testing using HPV tests and cytology testing (Pap tests) at age 60 and 65. Those who cannot access these tests can opt for three consecutive negative cytology tests, with the last test performed at age 65.
While cervical cancer is often treatable when detected early, barriers to screening remain a significant issue, particularly among women from historically underserved communities. By providing more accessible and convenient testing options, the American Cancer Society hopes to bridge this gap and help reduce the burden of cervical cancer in the US.